Explore

Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Trendline Trendline
Anteris Technologies Reports Q1 2026 Financial Results with Increased Net Loss

Anteris Technologies Reports Q1 2026 Financial Results with Increased Net Loss

Anteris Technologies Reports Q1 2026 Financial Results with Increased Net Loss
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients
Trendline Trendline
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates

Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates

Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration